Send us a text

Send us a text

Part 2 of our discussion on bladder cancer with Professor Rob Jones.

We have new drug classes in Bladder cancer !!

We look at Erdafitinib which is coming in the post Immunotherapy space to NHS England.

We also look ahead to Antibody Drug Conjugates - in particular Enfortumab Vedotin - with EV 302 trial results and what access to this means for the UK bladder community.

These are exciting times and we discuss potential side effects of these classes of drugs and how we intend to use them.

Enjoy

Send us a text

The Royal College of Radiologists celebrates 50 years of Royal Charter this year!!!

Join us as we explore 50 years of the RCR Royal Charter with the President - Dr Katharine Halliday and Vice President - Dr Tom Roques.

We look at the achievements of the Royal College of Radiologists have made over the years and look to the future of cancer care at the RCR.

We hear how the RCR is our voice as a community of Radiologists and Oncologists.

It guides our learning and sets the standards for our training and profession.

We even justify the membership fees for any sceptics.

In this our 50th episode of the Simply Oncology Podcast we celebrate the Royal College of Radiologists 50th anniversary of Royal Charter Status!!

Send us a text

Join us for this Simply Oncology is Back in Bladder Cancer with the amazing Prof Rob Jones.

Part 1 of 2 on a free ranging overview of metastatic bladder cancer treatment in the UK.

Cisplatin vs Carboplatin

Role of IO

2nd line chemo?

Send us a text

Join us for this episode where we explore Head and Neck cancers and their treatment.

This is a group of cancers from the mouth to the vocal cords and make up the 8th most common group of cancers in the UK.

Almost 13000 cases happen each year in the UK.

We discuss the major role that radiotherapy plays and the process and side effects.

Teamwork is a major component of Head and Neck cancer therapy.

We also discuss how immunotherapy has a role in advanced Head & Neck cancer.

A must listen for anyone supporting or being treated for Head & Neck cancer.

Send us a text

Welcome back for our 2nd part of our radiotherapy update on breast cancer.

We finish our discussion with Professor Mark Beresford who is Chair of the UK Breast Group.

We discuss the timing of radiotherapy around breast reconstruction.

We look at situations where we treat other areas such and above the collar bone (supraclavicular) or central area (internal mammary) areas.

We examine when radiotherapy may be offered after mastectomy.

We also look at when we may be able to avoid using radiotherapy after breast surgery in low risk cases.

Another must listen.

Send us a text

Join us for the first part of this 2 part masterclass in breast radiotherapy.

Breast radiotherapy is a major component of breast cancer treatment. It forms a large part of all radiotherapy delivered across cancer centres.

After removal of a breast tumour radiotherapy is offered to reduce the chance of local relapse of the cancer.

We talk to Professor Mark Beresford who is chair of the UK Breast Group about how breast radiotherapy has gone from 5 weeks of treatment to 1 week.

We talk about side effects and when we offer an extra radiotherapy boost to the area the tumour was.

We also discuss radiotherapy for reducing the risk of disease in the axilla (armpit) and the current surgery versus radiotherapy debate for that area.

This is a must listen for anyone wanting to learn more about breast radiotherapy.

Send us a text

Join us for the 2nd part of our discussion with Dr Olubukola (Bookie) Ayodele on health inequities in cancer care.

We look at potential steps to promote health equity.

Bookie introduces the concept of 'Cultural Competency' in helping health professionals discuss the very challenging topic that is cancer.

We hear how biological difference in blood results can play role in excluding back patients from certain chemotherapy trials.

We think about the stepwise change and education needed to make healthcare more accessible to all.

Enjoy